Wall Street brokerages expect Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Rating) to announce earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Monopar Therapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.25). Monopar Therapeutics posted earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The firm is expected to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Monopar Therapeutics will report full year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.23) to ($0.67). For the next financial year, analysts anticipate that the firm will report earnings of ($1.08) per share, with EPS estimates ranging from ($1.30) to ($0.86). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Monopar Therapeutics.
Monopar Therapeutics (NASDAQ:MNPR – Get Rating) last issued its quarterly earnings results on Thursday, March 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03).
Monopar Therapeutics stock opened at $2.18 on Friday. Monopar Therapeutics has a 12-month low of $2.00 and a 12-month high of $6.98. The firm’s fifty day moving average is $2.63 and its 200 day moving average is $3.36.
A hedge fund recently raised its stake in Monopar Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Rating) by 36.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,171 shares of the company’s stock after purchasing an additional 10,410 shares during the quarter. Geode Capital Management LLC owned 0.31% of Monopar Therapeutics worth $189,000 as of its most recent SEC filing. 1.62% of the stock is currently owned by hedge funds and other institutional investors.
About Monopar Therapeutics (Get Rating)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
- Get a free copy of the StockNews.com research report on Monopar Therapeutics (MNPR)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.